Inherited BRCA2 mutations in African Americans with breast and/or ovarian cancer: A study of familial and early onset cases

Human Genetics

Volumn 113, Issue 5, 2003, Pages 452-460

  Kanaan, Yasmine ^a   Kpenu, Elikem ^a   Utley, Kim ^b   Adams Campbell, Lucile ^b   Dunston, Georgia M ^a   Brody, Lawrence C ^c   Broome, Carolyn ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HOWARD UNIVERSITY CANCER CENTER   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GENETICS; CAUCASIAN; CONTROLLED STUDY; DNA FLANKING REGION; DNA SEQUENCE; EARLY CANCER; ETHNIC DIFFERENCE; EXON; FAMILIAL CANCER; FEMALE; GENE DELETION; GENETIC CODE; GENETIC SCREENING; GENETIC VARIABILITY; GERM LINE; HEREDITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; INTRON; MALE; MUTATION; MUTATION RATE; NEGRO; OVARY CANCER; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL SIGNIFICANCE; TUMOR SUPPRESSOR GENE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE OF ONSET; AGED; AMINO ACID SUBSTITUTION; BRCA2 PROTEIN; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; FRAMESHIFT MUTATION; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; OVARIAN NEOPLASMS; PEDIGREE; SEQUENCE DELETION; UNITED STATES; VARIATION (GENETICS);

EID: 0141989962     PISSN: 03406717     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00439-003-0999-0     Document Type: Article

References (38)

1. Baumbach-Reardon L, Gayol L, Scholl T, Basterrechea H, Smith S, Arena JF (2001) Completed BRCA1/BRCA2 mutation analysis reveals a low rate of germline mutation in at-risk African American families. Nat Genet 27:41-42
2. Begg CB (2002) On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 94:1221-1226 (Commentary 2003 J Natl Cancer Inst 95: 73-79)
3. Berman DB, Costalas J, Schultz DC, Grana G, Daly M, Goodwin AK (1996) A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals Cancer Res. 56:3409-3414
4. Breast Cancer Information Core (2003) An open access on-line breast cancer mutation data base, http://research.nhgri.nih.gov/bic/
5. Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316
6. Brody LC, Biesecker BB (1998) Breast cancer susceptibility genes BRCA1 and BRCA2. Medicine 77:208-226
7. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidden D, et al. (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13: 123-125
8. Easton DF (1994) The inherited component of cancer. Br Med Bull 50:527-535
9. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BAJ, Gayther SA (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72:1-12
10. Eeles RA, Stratton MR, Goldgar DE, Easton DF (1994) The genetics of familial breast cancer and their practical implications. Eur J Cancer 30:1383-1390
11. Eng C, Brody LC, Wagner TMU, Devilee P, Vijg J, Szabo C, Tavtigian SV, Nathanson KL, Ostrander E, Frank TS (2001) Interpreting epidemiological research: Blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 38:824-833
12. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayther SA, et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676-689
13. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A, et al. (1998) Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425
14. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490
15. Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, Ponder BAJ, Anton-Culver H (1997) Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60:313-319
16. Ganguly T, Citron M., Stott J, Isaacs C, Peshkin B, Godmilow L, Weber B, Ganguly A (1998) Novel BRCA mutations in African American individuals with breast and ovarian cancer. Am J Hum Genet 63(Suppl):A69
17. Gao Q, Tomlinson G, Das S, Cummings S, Sveen L, Fackenthal J, Schumm P, Olopade OI (2000) Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 107:186-191
18. Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, Van Welsem T, Van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, Van't Veer LJ, Pals G (2003) Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 63:1449-1453
19. Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Ollsson H (1999) Incidence of malignant tumors in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 35:1248-1257
20. Jorde LB, Bamshad M, Rogers AR (1998) Using mitochondrial and nuclear DNA markers to reconstruct human evolution. Bioessays 20:126-136
21. National Cancer Institute (2001) http://cis.nci.nih.gov/fact/5_6.htm
22. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC (1998) Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279:915-921
23. Nordling M, Karlsson P, Wahlstrom J, Engwall Y, Wallgren A, Martinsson T (1998) A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res 58:1372-1375
24. Olopade OI, Fackenthal JD, Dunston G, Tainsky M, Collins F, Whitfield-Broome C (2003) Breast cancer genetics in African Americans. Cancer (Suppl) 97:236-245
25. Panguluri RCK, Brody LC, Modali R, Utley K, Adams-Campbell L, Day AA, Whitfield-Broome C, Dunston GM (1999) BRCA1 mutations in African Americans. Hum Genet 105:28-31
26. Payne SR, Newman B, King M-C (2000) Complex germline rearrangement of BRCA1 associated with breast and ovarian cancer. Genes Chromosomes Cancer 29:58-62
27. Peelen T, Van Vliet M, Bosch A, Bignell G, Vasen HF, Klijn JG, Meijers-Heijboer H, Stratton M, Van Ommen GJ, Cornelisse CJ, Devilee P (2000) Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br J Cancer 82:151-156
28. Pellegrini L, Yu DS, Lo T, Anand S, Lee M, Blundell TL, Venkitaraman AR (2002) Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420:287-293
29. Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch HT, Lenoir GM, Mazoyer S (1999) Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res 59:455-461
30. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds) SEER Cancer Statistics Review 1973-1999 (2002) National Cancer Institute, Bethesda http://seer.cancer.gov/csr/1973_1999/
31. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
32. Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL, King MC (1997) BRCA2 in American families with four or more cases of breast or ovarian cancer: Recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60:1031-1040
33. Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Rebbeck TR, Armstrong KA, Calzone K, Stopfer J, Seal S, Stratton MR, Weber BL (2002) BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 20:994-999
34. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408
35. Thompson D, Easton D (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68:410-419
36. Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, Lenoir GM, Mazoyer S, Weber BL (2000) Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel eletrophoresis or sequencing. Am J Hum Genet 67:841-850
37. Wagner TMU, Hirtenlehner K, Shen P, Moeslinger R, Muhr D, Fleischmann E, Concin H, Doeller W, Haid A, Lang AH, Mayer P, Petru E, Ropp E, Langbauer G, Kubista E, Scheiner O, Underhill P, Mountain J, Steierer M, Zielinski C, Oefner P (1999) Global sequence diversity of BRCA2: Analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet 8:413-423
38. Yano K-I, Morotomi K, Saito H, Kato M, Matsuo F, Miki Y (2000) Nuclear localization signals of the BRCA2 protein. Biochem Biophys Res Commun 270:171-175